Key result
Sulforaphane plus ischemic postconditioning protects hypercholesterolemic hearts against reperfusion injury via Nrf2 and KLF pathways.
Why the study?
Does combined sulforaphane and ischemic postconditioning therapy protect the heart against reperfusion injury and maintain cardiac function in high-cholesterol-fed rats?
Does combined sulforaphane and ischemic postconditioning therapy protect the heart against reperfusion injury and maintain cardiac function in high-cholesterol-fed rats?
In a preclinical rat model of hypercholesterolemia, combining sulforaphane with ischemic postconditioning preserved cardiac function after myocardial infarction by reducing inflammation and restoring redox balance via Nrf2 and KLF4/15 modulation.
Answers are grounded in this paper and cite their sources.
No immediate clinical implications for reperfusion injury; leaves open translation of combined sulforaphane and postconditioning from hypercholesterolemic rat models.
Hypercholesterolemia (HC) is tightly associated with chronic inflammation and oxidative stress and contributes to coronary artery disease. HC can accelerate the progression of myocardial ischemia, compromising the effectiveness of protective strategies and making the myocardium more vulnerable to injury. Consequently, affecting the activation of protective mechanisms. Oxidative stress and chronic inflammation are closely interrelated; targeting both could be potentially effective for protecting the reperfused heart under HC. Among the effective strategies to alleviate oxidative damage in preclinical studies are sulforaphane (SFN) and ischemic postconditioning (iPostC). SFN is a bioactive compound that can induce protective mechanisms, such as the activation of nuclear factor erythroid 2-related factor 2 (Nrf2). Similarly, iPostC activates protective mechanisms to prevent reperfusion injury, including Nrf2 activation and inflammation diminishment, as demonstrated in healthy animal models. Therefore, there is a need to develop effective strategies to prevent myocardial damage in the presence of HC as a risk factor. This study evaluated the efficacy of combined SFN and iPostC therapy in protecting the heart against reperfusion injury in high-cholesterol-fed rats. We found that this combined strategy was associated with multitarget protective actions, correlating with attenuated inflammation, reduced nuclear accumulation of nuclear factor-κB (NF-κB) p65 and Krüppel-like factor (KLF)-5, restoration of redox balance, and increased nuclear levels of Nrf2, KLF4, and KLF15. These data support the maintenance of cardiac function following myocardial infarction in the setting of HC.
No takes yet. Share an insight, caveat, or question.
Zúñiga-Muñoz et al. (2026) studied Myocardial ischemia-reperfusion injury in hypercholesterolemic rats. Combined sulforaphane (SFN) and ischemic postconditioning (iPostC) was evaluated on Cardioprotection against reperfusion injury, redox balance, inflammation, and cardiac function maintenance. Combined sulforaphane and ischemic postconditioning protected high-cholesterol-fed rat hearts from reperfusion injury by increasing nuclear Nrf2, KLF4, and KLF15 and reducing NF-κB p65 and KLF5.
Synapse has enriched 10 related papers. Consider them for comparative context: